One of the biggest concerns about retatrutide is its effect on resting heart rate, with increases of 9–10 bpm. That’s 3x more compared to semaglutide or tirzepatide. While it sounds alarming, is this number really a cardiovascular risk?
An extra 10 beats a minute means if your resting rate is normally 80, on retatrutide it sits closer to 90. That adds up to roughly 14,000 extra heartbeats every day, or around 5 million more a year. In large studies, a 10 bpm increase in resting heart rate links to an 8-9% higher risk of mortality. Although that sounds alarming, these studies only show a correlation. Higher heart rates often correlate with lower fitness levels, poor sleep, or heavy caffeine use.
The real concern is that this increase in heart rate lasts. In the 2023 trial, heart rate climbed over 24 weeks, peaked, and stayed 6-7 beats higher than placebo at week 48. It seems to be a persistent shift. A 2026 trial in a non-diabetic population found nearly every other marker of heart health improves. Blood pressure down 12.3 points. Triglycerides down 41%, and non-HDL cholesterol over 24%. Standard blood tests look great, but heart rate is moving in the opposite direction.
So why does retatrutide have this effect when other GLP-1s don’t? The reason could be that semaglutide targets one receptor, GLP-1,and tirz targets GLP-1 and GIP. Retatrutide targets both, plus a 3rd: glucagon. No other approved obesity medication has utilized glucagon yet.
Research on healthy volunteers indicates that glucagon alone can raise heart rate by 13 bpm. However, scientists haven’t identified glucagon receptors in human heart tissue. This implies that the drug might influence the nervous system rather than directly affecting the heart.
The 2023 trial also monitored heart rhythm problems. About 2.9% of people on placebo had a rhythm event versus 11.3% on high-dose retatrutide. Most of these were mild. One serious case involved severe dehydration from vomiting, which can cause rhythm issues on its own. Headlines often leave out a key detail about the trial design. The study excluded anyone with a resting heart rate over 100, atrial fibrillation, severe heart failure, or recent heart attacks. This early safety data only applies to people with stable baseline heart health.
Semaglutide already has a trial testing whether a heart rate increase from these drugs can actually cause harm. In the SELECT trial of 17,000+ people with heart disease, resting rate went up 3 bpm. Yet major heart events still dropped 20%. The thing to keep in mind is the scale. Retatrutide’s effect on heart rate is roughly three times greater than that of semaglutide. We can’t automatically assume the same logic holds when the heart rate jump is that much bigger. It’s also worth noting where these numbers come from. The 9-10 bpm figure comes from the smaller 2023 phase 2 trial. Five phase 3 trials released weight loss and blood pressure data, but none have published their final heart rate numbers yet.
So far, the early outcomes data seems positive. In the TRIUMPH-3 trial, with 2,000 individuals with existing heart disease, there were 44 major heart events in the retatrutide group compared to 52 in the placebo group. The trial designed to settle this debate is called TRIUMPH Outcomes. It’s tracking 10,000 people with heart or kidney disease over several years to measure actual heart attack and stroke rates. It started in 2024, with full results expected around 2029.
If you’re generally healthy, the weight loss with big drops in blood pressure and cholesterol looks like a strong tradeoff. If you already have arrhythmias or a high heart rate, this drug will need careful clinical oversight once available.
Buy Retatrutide online here: Retatrutide for sale